Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients

Clinics

Volumn 68, Issue 5, 2013, Pages 665-673

  Sun, Jia Yin ^a   Zhai, Lin ^a   Li, Qiao Ling ^a   Ye, Jia Xin ^a   Kang, Li Na ^a   Xie, Jun ^a   Xu, Biao ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Acute Myocardial Infarction; Endothelial Progenitor Cell Inhibitors; Endothelial Progenitor Cells; Prognosis; Type 2 Diabetes Mellitus

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A;

AGED; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL; STEM CELL MOBILIZATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; C-REACTIVE PROTEIN; CHEMOKINE CXCL12; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERINDOPRIL; PROGNOSIS; PROSPECTIVE STUDIES; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878435072     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)14     Document Type: Article

References (37)

1. Shihara M, Tsutsui H, Tsuchihashi M, Tada H, Kono S, Takeshita A. Inhospital and one-year outcomes for patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2002;90(9):932-6, http://dx.doi.org/10.1016/S0002-9149(02)02656-5.
2. Morrow DA, Antman EM, Murphy SA, Qin J, Ruda M, Guneri S, et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J. 2007;154(6):1078-84, 84 e1, http://dx.doi.org/10.1016/j. ahj.2007.07.027.
3. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30(1):171-9, http://dx.doi.org/10.1016/S0735-1097(97)00118-6.
4. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J. 1984;108(1):31-7, http://dx.doi.org/10.1016/0002-8703(84)90541-6.
5. Lamblin N, Fertin M, de Groote P, Bauters C. Cardiac remodeling and heart failure after a first anterior myocardial infarction in patients with diabetes mellitus. J Cardiovasc Med (Hagerstown). 2012;13(6):353-9, http://dx.doi.org/10.2459/JCM.0b013e328353694b.
6. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22(10):1567-72, http://dx.doi.org/10.1161/01.ATV.0000036417.43987.D8.
7. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45(9):1449-57, http://dx.doi.org/10.1016/j.jacc.2004.11.067.
8. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005;105(1):199-206, http://dx.doi.org/10.1182/blood-2004-05-1831.
9. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/ CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006;98(3):e20-5, http:// dx.doi.org/10.1161/01.RES.0000205765.28940.93.
10. Ling L, Shen Y, Wang K, Jiang C, Fang C, Ferro A, et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS One. 2012;7(11):e50739, http://dx.doi.org/10.1371/journal.pone. 0050739.
11. You D, Cochain C, Loinard C, Vilar J, Mees B, Duriez M, et al. Combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide activate postnatal vasculogenesis in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008;325(3):766-73, http://dx.doi.org/10.1124/jpet.107.131532.
12. Muller P, Kazakov A, Jagoda P, Semenov A, Bohm M, Laufs U. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res. 2009;83(1):106-14, http://dx.doi.org/10.1093/cvr/cvp123.
13. Cacciatore F, Bruzzese G, Vitale DF, Liguori A, de Nigris F, Fiorito C, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011;67(9):877-83.
14. Wang CH, Verma S, Hsieh IC, Chen YJ, Kuo LT, Yang NI, et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol. 2006;41(1):34-43, http://dx.doi.org/10.1016/j.yjmcc.2006.03.006.
15. McConnell KJ, Humphries TL, Raebel MA, Merenich JA. Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Pharmacotherapy. 2003;23(12):1564-72, http://dx.doi.org/10.1592/phco.23.15.1564.31963.
16. Toblli JE, Cao G, DeRosa G, Di Gennaro F, Forcada P. Angiotensinconverting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens. 2004;17(2):172-80.
17. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107(9):1322-8, http://dx.doi.org/10.1161/01.CIR. 0000055313.77510.22.
18. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18(14):3964-72, http://dx.doi.org/10.1093/emboj/18.14.3964.
19. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285(15):1987-91, http://dx.doi.org/10. 1001/jama.285.15.1987.
20. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35(7):1109-18, http://dx.doi.org/10.1016/j.exphem.2007.04.002.
21. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol. 2007;27(7):1572-9, http://dx.doi.org/10.1161/ ATVBAHA.107.144972.
22. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 2003;108(21):2710-5, http://dx.doi.org/10. 1161/01.CIR.0000096490.16596.A6.
23. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600.
24. Thal MA, Krishnamurthy P, Mackie AR, Hoxha E, Lambers E, Verma S, et al. Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair. Circ Res. 2012;111(2):180-90, http://dx.doi.org/10.1161/CIRCRESAHA.112.270462.
25. Westenbrink BD, Oeseburg H, Kleijn L, van der Harst P, Belonje AM, Voors AA, et al. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther. 2008;22(4):265-74, http://dx.doi.org/10.1007/s10557-008-6094-y.
26. Davidson EP, Coppey LJ, Holmes A, Yorek MA. Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats. Eur J Pharmacol. 2012;677(1-3):180-7.
27. Gerc V, Buksa M. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases. Med Arh. 2010;64(5):295-9.
28. Rahman S, Ismail AA, Rahman AR. Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope? Int J Diabetes Dev Ctries. 2009;29(3):110-7, http://dx.doi.org/10.4103/0973-3930.54287.
29. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9(11):1370-6, http://dx.doi.org/10.1038/nm948.
30. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, et al. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol. 2011;301(5):F1114-23, http://dx.doi.org/10.1152/ajprenal.00122.2011.
31. Infanger M, Faramarzi S, Grosse J, Kurth E, Ulbrich C, Bauer J, et al. Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol. 2007;16(5):291-9, http://dx.doi.org/10.1016/j.carpath.2007.04.001.
32. Dong L, Kang L, Ding L, Chen Q, Bai J, Gu R, et al. Insulin modulates ischemia-induced endothelial progenitor cell mobilization and neovascularization in diabetic mice. Microvasc Res. 2011;82(3):227-36.
33. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 2001;97(11):3354-60, http://dx.doi.org/10.1182/blood.V97.11.3354.
34. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-9, http:// dx.doi.org/10.1161/01.CIR.0000053730.47739.3C.
35. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109(17):2058-67, http://dx.doi.org/10.1161/01.CIR.0000127577.63323. 24.
36. Chen J, Jin J, Song M, Dong H, Zhao G, Huang L. C-reactive protein down-regulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor for advanced glycation end-products. Gene. 2012;496(2):128-35, http://dx. doi.org/10.1016/j.gene.2011.12.039.
37. Tousoulis D, Kourtellaris P, Antoniades C, Vasiliadou C, Papageorgiou N, Tentolouris C, et al. Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patients with coronary artery disease. Int J Cardiol. 2008;124(1):127-9.